Journal article
Short- and long-term effects of imatinib in hospitalized COVID-19 patients: A randomized trial
Abstract
OBJECTIVES: We studied the short- and long-term effects of imatinib in hospitalized COVID-19 patients.
METHODS: Participants were randomized to receive standard of care (SoC) or SoC with imatinib. Imatinib dosage was 400 mg daily until discharge (max 14 days). Primary outcomes were mortality at 30 days and 1 year. Secondary outcomes included recovery, quality of life and long COVID symptoms at 1 year. We also performed a systematic review and …
Authors
Halme ALE; Laakkonen S; Rutanen J; Nevalainen OPO; Sinisalo M; Horstia S; Mustonen JMJ; Pourjamal N; Vanhanen A; Ala-Kokko T
Journal
Journal of Infection, Vol. 89, No. 3,
Publisher
Elsevier
Publication Date
September 2024
DOI
10.1016/j.jinf.2024.106217
ISSN
0163-4453